HYTN Launches GMP Stability Program and Validates Vape Cartridges for International Markets

HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF), a leader in pharmaceutical-grade cannabis manufacturing, has announced the launch of its Good Manufacturing Practice (GMP) Stability Program and the validation of its cannabis vape cartridges for international distribution. This strategic move builds upon the company's January 21, 2025, announcement of its partnership with SNDL Inc. to develop GMP-compliant vape products.

The Stability Program, conducted in collaboration with HYTN's GMP-licensed laboratory partner, aims to provide an initial six-month stability statement for GMP-compliant vape products. This is a crucial regulatory requirement for pharmaceutical and medical cannabis markets in Germany, the United Kingdom, and Australia. Ongoing non-accelerated stability studies will extend to 12 months, further validating long-term product stability for international markets.

In parallel with the launch of the Stability Program, HYTN has finalized the selection of a cartridge manufacturer and initiated comprehensive qualification and validation procedures. These efforts ensure compliance with GMP standards for HYTN's ceramic coil 1g vaporizer cartridge, establishing a foundation for global distribution while adhering to evolving regulations and market standards.

To support the expansion of its GMP product portfolio to include live resin and live rosin cannabis vape products, HYTN has submitted an amendment to its existing licensing framework with Health Canada to incorporate oil as an approved dosage form. This amendment, along with anticipated additional GMP approvals, reinforces the company's commitment to meeting the highest pharmaceutical and regulatory standards across global markets.

HYTN's initiatives position the company to meet the needs of global cannabis markets requiring GMP-certified products under strict regulatory frameworks. Germany's medical cannabis market has grown significantly, driven by increasing patient counts, expanding physician prescriptions, and broader pharmacy distribution. In Q3 2024, Germany imported 20,000 kilograms of cannabis—more than double the quarterly average before the April cannabis reform, highlighting the rising global demand for pharmaceutical-grade cannabis.

HYTN Innovations Inc. is a pharmaceutical company specializing in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. The company is dedicated to becoming a premier provider of these products across all federally regulated markets by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.

Good Manufacturing Practices (GMP) guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation.

In conclusion, HYTN's launch of the GMP Stability Program and validation of vape cartridges for international markets align with the company's long-term strategic goals. These initiatives position HYTN to meet the needs of global cannabis markets requiring GMP-certified products, expand its product portfolio, and strengthen its partnership with SNDL Inc. By adhering to GMP standards and conducting stability studies, HYTN ensures the quality, safety, and efficacy of its products, building consumer trust and brand loyalty in the global market.